The price of prevention: What now for immunisation against meningococcus B?

The Lancet

Volumn 382, Issue 9890, 2013, Pages 369-370

  Moxon, Richard ^a   Snape, Matthew D ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; MENINGOCOCCUS VACCINE; SIALIC ACID; VIRULENCE FACTOR;

BACTERIAL MENINGITIS; BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LIMB AMPUTATION; MENINGOCOCCEMIA; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; NEUROLOGICAL COMPLICATION; NOTE; PRIORITY JOURNAL; SKIN NECROSIS; SURVIVOR; UNITED KINGDOM; VACCINATION;

EID: 84881170759     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61572-X     Document Type: Note

References (17)

1. D Pace, AJ Pollard Meningococcal disease: clinical presentation and sequelae Vaccine 30 suppl 2 2012 B3 B9
2. Joint Committee on Vaccination and Immunisation JCVI interim position statement on use of Bexsero® meningococcal B vaccine in the UK. July, 2013 2013 Department of Health London https://www.gov.uk/government/publications/ jcvi-interim-position-statement-on-the-use-of-bexsero-meningococcal-b-vaccine- in-the-uk (accessed July 26, 2013).
3. Public Health England Invasive meningococcal infections (England and Wales), annual report for 2011/12. Health Protection Report vol 7, nos 18-22. 3, 10, 17, 24, and 31 May, 2013 http://www.hpa.org.uk/hpr/archives/2013/hpr18- 2213.pdf June 13, 2013 (accessed July 28, 2013).
4. AC Cohn, JR MacNeil, TA Clark Centers for Disease Control and Prevention (CDC) Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 62 RR-2 2013 1 28
5. SA Halperin, JA Bettinger, B Greenwood et al. The changing and dynamic epidemiology of meningococcal disease Vaccine 30 suppl 2 2012 B26 B36
6. J Finne, M Leinonen, PH Mäkelä Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis Lancet 2 1983 355 357
7. ER Moxon Applications of molecular microbiology to vaccinology Lancet 350 1997 1240 1244
8. V Masignani, R Rappuoli, M Pizza Reverse vaccinology: a genome-based approach for vaccine development Expert Opin Biol Ther 8 2002 895 905
9. MM Giuliani, J Adu-Bobie, M Comanducci et al. A universal vaccine for serogroup B meningococcus Proc Natl Acad Sci USA 103 2006 10834 10839
10. Committee for Medicinal Products for Human Use European Medicines Agency Assessment report: Bexsero, meningococcal group B vaccine http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/human/medicines/002333/human-med-001614. jsp&mid=WC0b01ac058001d124 Nov 15, 2012 (accessed July 29, 2013).
11. European Medicines Agency European Medicines Agency recommends approval of first vaccine for meningitis B http://www.ema.europa.eu/docs/en-GB/document- library/Press-release/2012/11/WC500134846.pdf Nov 16, 2012 (accessed July 26, 2013).
12. H Christensen, M Hickman, WJ Edmunds, CL Trotter Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact Vaccine 31 2013 2638 2646
13. KB Pouwels, E Hak, A van der Ende et al. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence Hum Vaccin Immunother 2013 published online Feb 13. http://dx.doi.org/10.4161/hv.23888
14. Novartis UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease, following JCVI interim recommendation on Novartis Bexsero® vaccine http://www.novartis.com/newsroom/media-releases/ 1718281.shtml July 24, 2013 (accessed July 29, 2013).
15. E Miller, D Salisbury, M Ramsay Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story Vaccine 20 suppl 1 2001 S58 S67
16. ER Moxon, CA Siegrist The next decade of vaccines: societal and scientific challenges Lancet 378 2011 348 359
17. MD Snape, D Medini, SA Halperin, L DeTora, J Drori, ER Moxon The challenge of post-implementation surveillance for novel meningococcal vaccines Vaccine 30 suppl 2 2012 B67 B72